- Home
- Publications
- Publication Search
- Publication Details
Title
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 9, Pages 2353
Publisher
MDPI AG
Online
2019-05-13
DOI
10.3390/ijms20092353
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Endocrine therapy in endometrial cancer: An old dog with new tricks
- (2019) Katarzyna J. Jerzak et al. GYNECOLOGIC ONCOLOGY
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
- (2018) G N Hortobagyi et al. ANNALS OF ONCOLOGY
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†
- (2018) F Cardoso et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer
- (2018) Carol Aghajanian et al. GYNECOLOGIC ONCOLOGY
- Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
- (2018) Stephanie M de Boer et al. LANCET ONCOLOGY
- Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
- (2018) Silvia Paola Corona et al. Drug Design Development and Therapy
- An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers
- (2018) Tahir Ali Chohan et al. BIOMEDICINE & PHARMACOTHERAPY
- Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer
- (2018) Antonella De Luca et al. Expert Opinion on Drug Metabolism & Toxicology
- Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i).
- (2018) Seth Andrew Wander et al. JOURNAL OF CLINICAL ONCOLOGY
- The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial
- (2018) Ben O'Leary et al. Cancer Discovery
- Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers
- (2018) Z. Ping Lin et al. Frontiers in Oncology
- Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment
- (2018) Jessica L.F. Teh et al. CLINICAL CANCER RESEARCH
- Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis
- (2017) Josee-Lyne Ethier et al. GYNECOLOGIC ONCOLOGY
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Palbociclib has antitumour effects on Pten- deficient endometrial neoplasias
- (2017) Maria Alba Dosil et al. JOURNAL OF PATHOLOGY
- Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations
- (2017) Laura M. Spring et al. ONCOLOGIST
- Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
- (2017) Gloria Mittica et al. Oncotarget
- The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer
- (2017) Tomohito Tanaka et al. PLoS One
- Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
- (2016) Emiliano Cocco et al. BRITISH JOURNAL OF CANCER
- Endometrial cancer: Not your grandmother's cancer
- (2016) Jessica N. McAlpine et al. CANCER
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
- (2016) Maria Teresa Herrera-Abreu et al. CANCER RESEARCH
- Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?
- (2016) Piera Gargiulo et al. CANCER TREATMENT REVIEWS
- Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis
- (2016) M. K. McConechy et al. CLINICAL CANCER RESEARCH
- A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
- (2016) J. R. Infante et al. CLINICAL CANCER RESEARCH
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
- (2016) A. Patnaik et al. Cancer Discovery
- Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth
- (2016) Frederik Holst et al. Scientific Reports
- ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
- (2015) N. Colombo et al. ANNALS OF ONCOLOGY
- Second-Line Therapy for Endometrial Cancer: The Need for Better Options
- (2015) Gini F. Fleming JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma
- (2015) Brian M. Slomovitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Global burden of cancer attributable to high body-mass index in 2012: a population-based study
- (2015) Melina Arnold et al. LANCET ONCOLOGY
- Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
- (2015) Ellen Stelloo et al. MODERN PATHOLOGY
- Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis
- (2015) Yanli Zhang et al. World Journal of Surgical Oncology
- Abstract 4756: In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer
- (2015) Neil A. O'Brien et al. CANCER RESEARCH
- CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
- (2014) Sadhna R. Vora et al. CANCER CELL
- CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
- (2014) A. DeMichele et al. CLINICAL CANCER RESEARCH
- Current opinion on bevacizumab on endometrial cancer treatment
- (2014) Stefano Bogliolo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Improving oncologic outcomes for women with endometrial cancer: Realigning our sights
- (2014) Sean C. Dowdy GYNECOLOGIC ONCOLOGY
- Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
- (2014) David N. Church et al. JNCI-Journal of the National Cancer Institute
- Classification of endometrial carcinoma: more than two types
- (2014) Rajmohan Murali et al. LANCET ONCOLOGY
- High expression of cyclin A is associated with poor prognosis in endometrial endometrioid adenocarcinoma
- (2014) Simi Santala et al. TUMOR BIOLOGY
- Cyclin-dependent kinases
- (2014) Marcos Malumbres GENOME BIOLOGY
- The Emerging Genomic Landscape of Endometrial Cancer
- (2013) M. Le Gallo et al. CLINICAL CHEMISTRY
- Cdks, cyclins and CKIs: roles beyond cell cycle regulation
- (2013) S. Lim et al. DEVELOPMENT
- Neoadjuvant treatment of endometrial cancer using anastrozole: A randomised pilot study
- (2013) Amudha Thangavelu et al. GYNECOLOGIC ONCOLOGY
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma
- (2013) S. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combined chemotherapy and radiation improves survival for node-positive endometrial cancer
- (2012) Larissa J. Lee et al. GYNECOLOGIC ONCOLOGY
- A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer
- (2012) Angeles Alvarez Secord et al. GYNECOLOGIC ONCOLOGY
- Estrogen and Progesterone Regulate p27kip1 Levels via the Ubiquitin-Proteasome System: Pathogenic and Therapeutic Implications for Endometrial Cancer
- (2012) Kuang-Tzu Huang et al. PLoS One
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
- (2011) C. Thangavel et al. ENDOCRINE-RELATED CANCER
- ER -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
- (2011) T. W. Miller et al. Cancer Discovery
- RB-pathway disruption in breast cancer
- (2010) Adam Ertel et al. CELL CYCLE
- Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias
- (2010) W. Blum et al. HAEMATOLOGICA
- Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial
- (2010) RA Nout et al. LANCET
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- Modified Radical Hysterectomy Versus Extrafascial Hysterectomy in the Treatment of Stage I Endometrial Cancer: Results From the ILIADE Randomized Study
- (2009) Mauro Signorelli et al. ANNALS OF SURGICAL ONCOLOGY
- Cyclin-dependent kinases: a family portrait
- (2009) Marcos Malumbres et al. NATURE CELL BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started